osmo - adalat 20 mg
bayer israel ltd - nifedipine - tablets prolonged release - nifedipine 20 mg - nifedipine - nifedipine - chronic stable angina, hypertension.
gynera
bayer israel ltd - ethinylestradiol; gestodene - coated tablets - ethinylestradiol 0.03 mg; gestodene 0.075 mg - ethinylestradiol - ethinylestradiol - hormonal contraception.
qlair
bayer israel ltd - dienogest; dienogest; estradiol valerate; estradiol valerate; estradiol valerate - film coated tablets - estradiol valerate 1 mg; estradiol valerate 3 mg; dienogest 2 mg; dienogest 3 mg; estradiol valerate 2 mg - estradiol - estradiol - oral contraception.treatment of heavy menstrual bleeding in women without organic pathology who desire oral contraception.
levitra 10 mg orodispersible tablets
bayer israel ltd - vardenafil as hydrochloride trihydrate - tablets orodispersible - vardenafil as hydrochloride trihydrate 10 mg - vardenafil - vardenafil - treatment of erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance. in order for levitra to be effective, sexual stimulation is required. not indicated for use by women.
betaferon
bayer israel ltd - interferon beta 1b - powder and solvent for solution for injection - interferon beta 1b 0.3 mg/vial - interferon beta-1b - interferon beta-1b - use in ambulatory patients with relapsing-remitting multiple sclerosis (rrms) and relapsing progressive m.s. to reduce the frequency of clinical exacerbations. treatment of secondary progressive (sp) form of multiple sclerosis. treatment of patients who have experienced a single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, including the prescence of mri abnormalities characteristic of m.s. and if they are determined to be at high risk of developing clinically definite multiple sclerosis.
eylea
bayer israel ltd - aflibercept - solution for intravitreal injection - aflibercept 40 mg/ml - aflibercept - eylea is indicated for adults for the treatment of • neovascular (wet) age-related macular degeneration (amd)• visual impairment due to macular oedema secondary to retinal vein occlusion (branch crvo or central rvo)• visual impairment due to diabetic macular oedema (dme)• visual impairment due to myopic choroidal neovascularisation (myopic cnv).
gynera
bayer israel ltd - ethinylestradiol; gestodene - coated tablets - ethinylestradiol 0.03 mg; gestodene 0.075 mg - ethinylestradiol - hormonal contraception.
kovaltry 1000 iu
bayer israel ltd - recombinant human coagulation factor viii - powder and solvent for solution for injection - recombinant human coagulation factor viii 1000 iu - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). kovaltry can be used for all age groups.
kovaltry 2000 iu
bayer israel ltd - recombinant human coagulation factor viii - powder and solvent for solution for injection - recombinant human coagulation factor viii 2000 iu - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). kovaltry can be used for all age groups.
kovaltry 250 iu
bayer israel ltd - recombinant human coagulation factor viii - powder and solvent for solution for injection - recombinant human coagulation factor viii 250 iu - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). kovaltry can be used for all age groups.